Epidemiology of severe hospital-acquired infections in patients with liver cirrhosis: Effect of long-term administration of norfloxacin

Clinical Infectious Diseases

Volumn 26, Issue 5, 1998, Pages 1066-1070

  Campillo, Bernard ^a   Dupeyron, Catherine ^b   Richardet, Jean Philippe ^b   Mangeney, Nicole ^b   Leluan, Georges ^b  

^a Hopital Albert Chenevier   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

NORFLOXACIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; ENTEROBACTERIACEAE; EPIDEMIOLOGY; FEMALE; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HUMAN; LIVER CIRRHOSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STAPHYLOCOCCUS; SURVIVAL; TREATMENT OUTCOME;

EID: 0031947403     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/520273     Document Type: Article

References (23)

1. Caly WR, Strauss E. A prospective study of bacterial infections in patients with cirrhosis. J Hepatol 1993;18:353-8.
2. Andreu M, Sola R, Sitges-Serra A, et al. Risk factors for spontaneous bacterial peritonitis in cirrhotic patients with ascites. Gastroenterology 1993;104:1133-8.
3. Rimola A, Bory F, Teres J, Peres-Ayuso RM, Arroyo V, Rodes J. Oral nonabsorbable antibiotics prevent infection in cirrhotics with gastrointestinal hemorrhage. Hepatology 1985;5:463-7.
4. Gines P, Rimola A, Planas R, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990;12:716-24.
5. Soriano G, Guarner C, Teixido M, et al. Selective intestinal decontamination prevents spontaneous bacterial peritonitis. Gastroenterology 1991;100:477-81.
6. Singh N, Gayowski T, Yu VL, Wagener MM. Trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial. Ann Intern Med 1995;122:595-8.
7. Rolachon A, Cordier L, Bacq Y, et al. Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial. Hepatology 1995;22:1171-4.
8. Runyon BA. Spontaneous bacterial peritonitis: an explosion of information. Hepatology 1988;8:171-5.
9. Bar-Meir S, Lerner R, Conn NO. Analysis of ascitic fluid in cirrhosis. Dig Dis Sci 1979;24:136-44.
10. Pelletier G, Lesur G, Ink O, et al. Asymptomatic bacterascites: is it spontaneous bacterial peritonitis? Hepatology 1991;14:112-5.
11. Chu CM, Chang KY, Liaw YF. Prevalence and prognostic significance of bacterascites in cirrhosis with ascites. Dig Dis Sci 1995;40:561-5.
12. Llovet JM, Rodriguez-Iglesias P, Moitinho E, et al. Spontaneous bacterial peritonitis in patients with cirrhosis undergoing selective intestinal decontamination. J Hepatol 1997;26:88-95.
13. Novella M, Sola R, Soriano G, et al. Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin. Hepatology 1997;25:532-6.
14. Felisart J, Rimola A, Arroyo V, et al. Cefotaxime is more effective than is ampicillin-tobramycine in cirrhotics with severe infections. Hepatology 1985;5:457-62.
15. Rimola A, Salmeron JM, Clemente G, et al. Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: results of a prospective, randomized, multicenter study. Hepatology 1995;21:674-9.
16. Carratala J, Fernandez-Sevilla A, Tubau F, Dominguez MA, Gudol F. Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis. Antimicrob Agents Chemother 1994;38:340-4.
17. Carratala J, Fernandez-Sevilla A, Tuban F, Callis M, Gudiol F. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 1995;20:557-60.
18. Dupeyron C, Mangeney N, Sedrati L, Campillo B, Fouet P, Leluan G. Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis. Antimicrob Agents Chemother 1994;38:340-4.
19. Wolff M, Bure A, Pathe JP, et al. Evolution des résistances bactériennes à la pefloxacine dans le service de Réanimation de l'Hôpital Claude Bernard. In: Pocidalo JJ, Vachon F, Régnier B, eds. Les nouvelles quinolones. Paris: Arnette, 1985:213-26.
20. Kotilainen P, Huovinen S, Järvinen H, Aro H, Huovinen P. Epidemiology of the colonization of inpatients and outpatients with ciprofloxacin-resistant coagulase-negative staphylococci. Clin Infect Dis 1995;21:685-7.
21. Voss A, Doebbeling BN. The worldwide prevalence of methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents 1995;5:101-6.
22. Navasa M, Folio A, Llovet JM, et al. Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology 1996;111:1011-7.
23. Garcia-Tsao G. Treatment of spontaneous bacterial peritonitis with oral ofloxacin: inpatient or outpatient therapy. Gastroenterology 1996;111:1147-50.